[Cancer of the prostate: evaluation of the expression of the mutated protein of the 53 tumor suppressor gene].
Prostate cancer is the most common tumour in men, and is most frequently established late in life. The objective of the article is to determine the protein expression of gene p53 in prostate cancer and to correlate the findings with clinical, morphological and epidemiological parameters. Immunohistochemical techniques with monoclonal antibody used to study the gene p53 expression. The study included 35 prostate carcinoma: 4 cases in stage A; 5 cases in stage B; 12 in stage C and 14 in stage D. The control group consisted in 10 benign prostate hyperplasia. Average age was 66.8 (SD +/- 6.7 years). Positive staining for gene p53 protein was seen in 11 of the 35 cases (31.4%). All stage A and B tumours were negative; however, stage C and D tumours were positive in 16 and 64% cases respectively. In the control group all cases were gene p53 negative. No statistical relationship was seen between Gleason Index and positive results for p53. There was a significant difference between gene 53 expression and clinical stage. Results show that the immunohistochemical expression of gen p53 mutated protein keeps no relation to Gleason's rating index and is seen with significantly higher frequency in advanced, primarily stage D tumours.